key: cord-0994061-dzpn1159 authors: Goncharova, Ekaterina A.; Dedkov, Vladimir G.; Dolgova, Anna S.; Kassirov, Ilia S.; Safonova, Marina V.; Voytsekhovskaya, Yana; Totolian, Areg A. title: One‐step quantitative RT‐PCR assay with armored RNA controls for detection of SARS‐CoV‐2 date: 2020-10-05 journal: J Med Virol DOI: 10.1002/jmv.26540 sha: 0ba51b6e8684ee51531713af6be7ea8a8238868c doc_id: 994061 cord_uid: dzpn1159 Coronavirus disease 2019 (COVID‐19) has become pandemic since March 11, 2020. Thus, development and integration in clinics of fast and sensitive diagnostic tools are essential. The aim of the study is a development and evaluation of a one‐step quantitative reverse transcription‐polymerase chain reaction (RT‐qPCR) assay (COVID‐19 Amp) for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) detection with an armored positive control and internal controls constructed from synthetic MS2‐phage‐based RNA particles. The COVID‐19 Amp assay limit of detection was 10(3) copies/ml, the analytical specificity was 100%. A total of 109 biological samples were examined using COVID‐19 Amp and World Health Organization (WHO)‐based assay. Discordance in nine samples was observed (negative by the WHO‐based assay) and discordant samples were retested as positive according to the results obtained from the Vector‐PCRrv‐2019‐nCoV‐RG assay. The developed COVID‐19 Amp assay has high sensitivity and specificity, includes virus particles‐based controls, provides the direct definition of the SARS‐CoV‐2 RdRp gene partial sequence, and is suitable for any hospital and laboratory equipped for RT‐qPCR. The mode of transmission is through direct contact and droplet spread. 14 In addition, SARS-CoV-2 showed the stability in aerosols (<5 μm) for at least up to 3 h and may be more stable on plastic and stainless steel than on copper and cardboard. 15 Accurate diagnosis of COVID-19 cannot be set based on symptoms due to their nonspecificity. According to the Guan et al. 16 report, 44% of 1099 COVID-19 patients from China exposed a fever when they entered the hospital and 89% developed a fever while in hospital. Thus, diagnostics can play an important role in the localization of COVID-19, ensuring the rapid implementation of control measures limiting spread through isolation and contact tracing. The most widely used diagnosing and screening COVID-19 techniques are nucleic acid testing and computer tomography (CT) scans. 16, 17 However, molecular techniques are more suitable than syndromic testing targeting specific pathogens when CT scans can only provide an approximate pathology. 18 Real-time quantitative polymerase chain reaction with reverse transcription (RT-qPCR) is a widely used technique to detect viral pathogens. As for COVID-19 diagnostics, RT-qPCR could target several conserved regions of SARS-CoV-2 genome [19] [20] [21] [22] : (1) 23 The assay also could involve twotarget system detection, where a first primer set detects numerous coronaviruses including SARS-CoV-2 and a second primer set is unique for SARS-CoV-2. 24 Leastwise 11 nucleic-acid-based methods have been approved in China by the National Medical Products Administration for diagnosing SARS-CoV-2. 25 Nevertheless, RT-qPCR is the most generally used method for detecting COVID-19 in respiratory samples. 26 Patients with clinical manifestations of acute respiratory viral infection symptoms were tested for SARS-CoV-2 using RT-qPCR de- The total volume of reaction mix for the sample was 25 µl containing the and PCR (C−) was used to exclude false-positive results due to possible or unintentional cross-contamination. The complementary DNA (cDNA; 113 bp) of SARS-CoV-2 RNAdependent RNA polymerase gene region that included the primers and probe-target sequences was constructed using previously developed step-out amplification. 28 To evaluate the efficiency of RNA extraction, an ICS was added to the analyzed samples. The ICS is an artificial RNA sequence (150-170 nt, guanine-cytosine content 50%; see Table 1 ), surrounded by an MS2-derived protective protein coat. The limit of detection (LOD) of the SARS-CoV-2 assay was determined using a series of 10-fold dilutions of ARPs (described above). In particular, 10-fold RNase-free water-diluted ARPs of known concentrations with the final volume of 100 μl were extracted using the RIBO-Prep Extraction Kit (AmpliSens), in accordance with the manufacturer′s instructions, and then tested using the SARS-CoV-2 assay to establish the standard curves and LOD. The LOD was set as the minimal dilution detected in three replicates. 31 The absence of cross-reactivity was proved by negative results of the viral panel detection that contained solutions of viral RNA and DNA from seven viral species. The analytical specificity of the COVID-19 Amp assay was determined as 100%. The summary of RNA or DNA of viruses that were examined in the study is shown in Table 2 . The COVID-19 Amp assay diagnostic sensitivity and specificity were determined using the detection of RNA extracted from GONCHAROVA ET AL. Table 3 ). The 95% confidence interval for a proportion was calculated according to Robert G. Newcombe. 32 In addition, for discordant samples verification, we applied another diagnostic assay Vector-PCRrv-2019-nCoV-RG (Vector) that is widely used for COVID-19 diagnostics in Russia. Conducted multiple alignments of the sequences of SARS-CoV-2 available in the GenBank enabled the identification of highly conserved regions for the designing of the SARS-CoV-2-specific primers and respective probes (Table 1) Table 5 . Some announced assays declare very low LOD, however the most typical sensitivity of viral RT-qPCR usually is not less than 10 3 copies/ml. 35 Therefore, there is a lack of diagnostic kits with sufficient The ongoing increase in cases of COVID-19 around the world now is driven by local transmission. 36 The data that support the findings of this study are available from the corresponding author upon reasonable request. The study has been evaluated and approved by the Local Ethics Committees of the Pasteur Institute, Saint Petersburg, Russia. Ekaterina A. Goncharova https://orcid.org/0000-0002-4891-0439 Ilia S. Kassirov https://orcid.org/0000-0003-4736-2183 Coronavirus disease 2019 ?FileName=147724713480104 46663889.xml. Accessed Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China virology, and clinical features of severe acute respiratory syndrome-coronavirus-2 (SARS-COV-2; coronavirus disease-19) Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Angiotensinconverting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target A pneumonia outbreak associated with a new coronavirus of probable bat origin Clinical features of patients infected with 2019 novel coronavirus in Wuhan Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan Potential of large "first generation" humanto-human transmission of 2019-nCoV Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1 Clinical characteristics of coronavirus disease 2019 in China COVID-19 pneumonia: what has CT taught us? Patients with RT-PCR confirmed COVID-19 and normal chest CT Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Miller MB Point-counterpoint: should we be performing metagenomic next-generation sequencing for infectiousdisease diagnosis in the clinical laboratory? A new coronavirus associated with human respiratory disease in China Coronavirus and the race to distribute reliable diagnostics Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19 RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens Diagnosing COVID-19: the disease and tools for detection The ultimate qPCR experiment: producing publication quality, reproducible data the first time Development and evaluation of a real-time RT-PCR assay for the detection of Ebola virus (Zaire) during an Ebola outbreak in Guinea in 2014-2015 Preparation of his-tagged armored RNA phage particles as a control for real-time reverse transcription-PCR detection of severe acute respiratory syndrome coronavirus Dubois DB Armored RNA technology for production of ribonuclease-resistant viral RNA controls and standards Ebola virus disease diagnosis by real-time RT-PCR: a comparative study of 11 different procedures Two-sided confidence intervals for the single proportion: comparison of seven methods Comparison of seven commercial RT-PCR diagnostic kits for COVID-19 Chinese Center for Disease Control and Prevention. Primers and probes for detection 2019-nCoV World Health OrganizationManual for the Laboratory-Based Surveillance of Measles, Rubella, and Congenital Rubella Syndrome Community transmission of severe acute respiratory syndrome coronavirus 2 Presumed asymptomatic carrier transmission of COVID-19 Viral load of SARS-CoV-2 in clinical samples First case of 2019 novel coronavirus in the United States One-step quantitative RT-PCR assay with armored RNA controls for detection of SARS-CoV-2